JO3766B1 - منشط مستقبل أسيتيل كولين الفا - 7 النيكوتيني - Google Patents
منشط مستقبل أسيتيل كولين الفا - 7 النيكوتينيInfo
- Publication number
- JO3766B1 JO3766B1 JOP/2012/0311A JOP20120311A JO3766B1 JO 3766 B1 JO3766 B1 JO 3766B1 JO P20120311 A JOP20120311 A JO P20120311A JO 3766 B1 JO3766 B1 JO 3766B1
- Authority
- JO
- Jordan
- Prior art keywords
- alpha
- acetylcholine receptor
- nicotinic acetylcholine
- receptor activator
- predicting
- Prior art date
Links
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 title abstract 2
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 title abstract 2
- 239000012190 activator Substances 0.000 title 1
- 229940122578 Acetylcholine receptor agonist Drugs 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000004797 therapeutic response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549319P | 2011-10-20 | 2011-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3766B1 true JO3766B1 (ar) | 2021-01-31 |
Family
ID=47297333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2012/0311A JO3766B1 (ar) | 2011-10-20 | 2012-10-18 | منشط مستقبل أسيتيل كولين الفا - 7 النيكوتيني |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2768507B1 (enExample) |
| JP (1) | JP6162705B2 (enExample) |
| KR (1) | KR102043077B1 (enExample) |
| CN (1) | CN103930112B (enExample) |
| AU (1) | AU2012324458B2 (enExample) |
| BR (1) | BR112014007485B1 (enExample) |
| CA (2) | CA2852268C (enExample) |
| EA (1) | EA034964B1 (enExample) |
| ES (1) | ES2776996T3 (enExample) |
| IN (1) | IN2014CN03647A (enExample) |
| JO (1) | JO3766B1 (enExample) |
| MX (1) | MX374644B (enExample) |
| TW (1) | TWI635861B (enExample) |
| WO (1) | WO2013057687A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| CN107106542B (zh) | 2014-10-20 | 2020-05-08 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
| NZ746468A (en) | 2016-04-07 | 2023-06-30 | Oyster Point Pharma Inc | Methods of treating ocular conditions |
| US11433057B2 (en) * | 2016-05-20 | 2022-09-06 | Vanda Pharmaceuticals Inc. | Method for improving or enhancing cognition |
| CN107188900B (zh) * | 2017-05-27 | 2019-09-06 | 北京师范大学 | α7烟碱型乙酰胆碱受体的配体化合物及其应用 |
| CN113840569B (zh) | 2019-03-19 | 2025-01-07 | 剑桥认知有限公司 | 诊断精神病症和推荐用于精神病症的治疗的方法和用途 |
| CN116731008B (zh) * | 2023-06-15 | 2025-10-24 | 西北大学 | 标记肺癌靶点烟碱型乙酰胆碱受体的免洗型荧光探针及制备方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US5075216A (en) | 1988-09-23 | 1991-12-24 | Cetus Corporation | Methods for dna sequencing with thermus aquaticus dna polymerase |
| ATE267877T1 (de) | 1993-01-07 | 2004-06-15 | Sequenom Inc | Dns - sequenzierung durch massenspektronomie |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| EP1303636A1 (en) | 2000-04-05 | 2003-04-23 | Glaxo Group Limited | Iterative analysis of non-responding population in the design of pharmacogenetic studies |
| GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| DE10156719A1 (de) | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| DE10211416A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Essig- und Propionsäureamide |
| DE10211415A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
| DE10234424A1 (de) | 2002-07-29 | 2004-02-12 | Bayer Ag | Benzothiophen-, Benzofuran- und Indolharnstoffe |
| GB0220581D0 (en) * | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| CA2499128C (en) | 2002-09-25 | 2012-07-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| WO2006065233A1 (en) | 2004-12-10 | 2006-06-22 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| TW200813067A (en) | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| NZ573735A (en) | 2006-05-19 | 2011-10-28 | Abbott Lab | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| WO2009066107A1 (en) | 2007-11-21 | 2009-05-28 | Astrazeneca Ab | Use of a nicotinic receptor agonist |
| WO2010043515A1 (en) | 2008-10-13 | 2010-04-22 | F. Hoffmann-La Roche Ag | Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1h-3-indazolecarboxylic acid amides |
| CN102209540A (zh) | 2008-11-11 | 2011-10-05 | 塔加西普特公司 | 使用α7-选择性配体的治疗方法 |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| TWI558398B (zh) * | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α７活化劑之用途 |
-
2012
- 2012-10-18 IN IN3647CHN2014 patent/IN2014CN03647A/en unknown
- 2012-10-18 JP JP2014536391A patent/JP6162705B2/ja active Active
- 2012-10-18 CA CA2852268A patent/CA2852268C/en active Active
- 2012-10-18 JO JOP/2012/0311A patent/JO3766B1/ar active
- 2012-10-18 BR BR112014007485-2A patent/BR112014007485B1/pt active IP Right Grant
- 2012-10-18 EA EA201490832A patent/EA034964B1/ru unknown
- 2012-10-18 CA CA3083244A patent/CA3083244C/en active Active
- 2012-10-18 WO PCT/IB2012/055692 patent/WO2013057687A2/en not_active Ceased
- 2012-10-18 EP EP12797979.7A patent/EP2768507B1/en active Active
- 2012-10-18 ES ES12797979T patent/ES2776996T3/es active Active
- 2012-10-18 MX MX2014004621A patent/MX374644B/es active IP Right Grant
- 2012-10-18 CN CN201280051452.1A patent/CN103930112B/zh active Active
- 2012-10-18 KR KR1020147010115A patent/KR102043077B1/ko active Active
- 2012-10-18 AU AU2012324458A patent/AU2012324458B2/en active Active
- 2012-10-19 TW TW101138792A patent/TWI635861B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201322980A (zh) | 2013-06-16 |
| CN103930112B (zh) | 2018-11-09 |
| MX374644B (es) | 2025-03-06 |
| BR112014007485B1 (pt) | 2022-05-31 |
| CA2852268C (en) | 2020-08-25 |
| AU2012324458B2 (en) | 2016-05-19 |
| IN2014CN03647A (enExample) | 2015-10-09 |
| EP2768507B1 (en) | 2019-12-11 |
| ES2776996T3 (es) | 2020-08-03 |
| CA3083244A1 (en) | 2013-04-25 |
| WO2013057687A2 (en) | 2013-04-25 |
| EA201490832A1 (ru) | 2015-12-30 |
| CN103930112A (zh) | 2014-07-16 |
| EA034964B1 (ru) | 2020-04-13 |
| AU2012324458A1 (en) | 2014-05-01 |
| JP2015501306A (ja) | 2015-01-15 |
| KR20140081822A (ko) | 2014-07-01 |
| WO2013057687A3 (en) | 2013-07-11 |
| JP6162705B2 (ja) | 2017-07-12 |
| EP2768507A2 (en) | 2014-08-27 |
| BR112014007485A2 (pt) | 2017-04-04 |
| KR102043077B1 (ko) | 2019-11-11 |
| MX2014004621A (es) | 2014-08-22 |
| CA3083244C (en) | 2023-01-03 |
| CA2852268A1 (en) | 2013-04-25 |
| TWI635861B (zh) | 2018-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN03647A (enExample) | ||
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| JO3715B1 (ar) | منشط مستقبل اسيتيل كولين الفا-7 النيكوتيني | |
| CY1120246T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
| MX355543B (es) | Macrociclos peptidomiméticos. | |
| UA107827C2 (xx) | Антитіло до cd40 | |
| PH12014501844A1 (en) | Peptidomimetic macrocycles | |
| PH12014500841B1 (en) | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE | |
| BR112013021863A2 (pt) | anticorpos anti-receptor il-6 e métodos de uso | |
| NZ720949A (en) | Methods and compositions for treating aging-associated conditions | |
| MX376663B (es) | Anticuerpos anti fc similar a receptor 5 (fcrh5). | |
| MX353143B (es) | Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b. | |
| WO2014138429A3 (en) | Peptidomimetic macrocycles and use thereof in regulating hif1alpha | |
| EP2560660A4 (en) | THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS | |
| MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
| WO2011154139A3 (en) | Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment | |
| WO2012173846A3 (en) | Peptidomimetic macrocycles | |
| BR112012032796A2 (pt) | miméticos niacina, e os métodos de utilização dos mesmos | |
| MX2014014161A (es) | Composicion para reducir la sensacion de trpa1 y trpv1. | |
| MX2016013372A (es) | Metodos de tratar selectivamente el asma utilizando antagonistas de il-13. | |
| UY34271A (es) | Anticuerpos anti-tie2 y usos de los mismos | |
| WO2013160315A3 (en) | Genetic predictors of response to treatment with crhr1 antagonists | |
| MX2014014376A (es) | Anticuerpos de anti-biotina y metodos de uso. | |
| WO2012122165A3 (en) | Substituted n-aryl pyridinones | |
| WO2016066634A3 (en) | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer |